Clinical trial
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic…
NCT00425386 · OHSU Knight Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00425386 |
|---|---|
| Title | Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer |
| Official title | A Dose Escalation Phase II Study of Sunitinib Plus Erlotinib in Advanced Renal Carcinoma |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug, Procedure |
| Interventions | erlotinib hydrochloride, sunitinib malate, biopsy |
| Enrollment | 60 |
| Start date | Aug 1, 2006 |
| Primary completion | Aug 1, 2010 |
| Completion | Mar 1, 2014 |
| First posted | Jan 23, 2007 |
| Last update posted | May 3, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: